Omnicell CFO Sells $187,768 in Stock (OMCL)
Omnicell (NASDAQ:OMCL) CFO Robin Gene Seim sold 7,664 shares of Omnicell stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $24.50, for a total value of $187,768.00. Following the transaction, the chief financial officer now directly owns 69,700 shares of the company’s stock, valued at approximately $1,707,650. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
OMCL has been the subject of a number of recent research reports. Analysts at B. Riley downgraded shares of Omnicell from a “buy” rating to a “neutral” rating in a research note to investors on Thursday, September 26th. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Omnicell in a research note to investors on Wednesday, August 21st. They now have a $24.00 price target on the stock. Finally, analysts at Cowen and Company raised their price target on shares of Omnicell from $18.00 to $21.00 in a research note to investors on Friday, August 2nd. They now have a “market perform” rating on the stock. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $23.00.
Shares of Omnicell (NASDAQ:OMCL) traded down 2.26% during mid-day trading on Friday, hitting $23.80. 209,004 shares of the company’s stock traded hands. Omnicell has a 52-week low of $12.33 and a 52-week high of $23.39. The stock’s 50-day moving average is $22.65 and its 200-day moving average is $19.76. The company has a market cap of $829.2 million and a P/E ratio of 38.65.
Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, August 1st. The company reported $0.27 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.25 by $0.02. The company had revenue of $93.70 million for the quarter, compared to the consensus estimate of $92.42 million. During the same quarter in the previous year, the company posted $0.20 earnings per share. The company’s revenue for the quarter was up 24.3% on a year-over-year basis.
Omnicell, Inc (NASDAQ:OMCL) is a provider of automated solutions for hospital medication and supply management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.